Una revisión de sus acciones específicas | 08 DIC 14

Nicotina: sus efectos sobre la salud

Sus mecanismos de acción, los efectos sobre los sistemas cardiovascular y nervioso central. La dependencia y su tratamientos disponibles.
Autor/a: Drug and Therapeutics Bulletin Editorial Office, London WC1H 9JR, UK Fuente: BMJ 2014;349:2014.7.0264rep Nicotine and health
INDICE:  1.  | 2. Referencias

1. Nigam M, Aschebrook-Kilfoy B, Shikanov S, Eggener S. Increasing incidence of testicular cancer in the United States and Europe from 1992 to 2009. World J Urol 2014 July 17 (Epub ahead of print).
2. Gilbert D, Rapley E, Shipley J. Testicular germ cell tumours: predisposition genes and the male germ cell niche. Nat Rev Cancer 2011; 11: 278-88.
3. Dalgaard MD, Weinhold N, Edsg.rd D, et al. A genome-wide association study of men with symptoms of testicular dysgenesis syndrome and its network biology interpretation. J Med Genet 2012; 49: 58-65.
4. Hemminki K, Li X. Familial risk in testicular cancer as a clue to a heritable and environmental aetiology. Br J Cancer 2004; 90: 1765-70.
5. Pettersson A, Richiardi L, Nordenskjold A, Kaijser M, Akre O. Age at surgery for undescended testis and risk of testicular cancer. N Engl J Med 2007; 356:1835-41.
6. Lip SZ, Murchison LE, Cullis PS, Govan L, Carachi R. A meta-analysis of the risk of boys with isolated cryptorchidism developing testicular cancer in later life. Arch Dis Child 2013; 98: 20-6.
7. Chieffi P, Chieffi S. Molecular biomarkers as potential targets for therapeutic strategies in human testicular germ cell tumors: an overview. J Cell Physiol 2013; 228: 1641-6.
8. Rajpert-De Meyts E. Developmental model for the pathogenesis of testicular carcinoma in situ: genetic and environmental aspects. Hum Reprod Update 2006; 12: 303-23.
9. Sperger JM, Chen X, Draper JS, et al. Gene expression patterns in human embryonic stem cells and human pluripotent germ cell tumors. Proc Natl Acad Sci U S A 2003; 100: 13350-5.
10. Almstrup K, Hoei-Hansen CE, Wirkner U, et al. Embryonic stem cell-like features of testicular carcinoma in situ revealed by genome-wide gene expression profiling. Cancer Res 2004; 64: 4736-43.
11. Kanetsky PA, Mitra N, Vardhanabhuti S, et al. Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer. Nat Genet 2009; 41: 811-5.
12. Turnbull C, Rapley EA, Seal S, et al. Variants near DMRT1, TERT and ATF7IP are associated with testicular germ cell cancer. Nat Genet 2010; 42: 604-7.
13. Kratz CP, Han SS, Rosenberg PS, et al. Variants in or near KITLG, BAK1, DMRT1, and TERT-CLPTM1L predispose to familial testicular germ cell tumour. J Med Genet 2011; 48: 473-6.
14. Rapley EA, Turnbull C, Al Olama AA, et al. A genome-wide association study of testicular germ cell tumor. Nat Genet 2009; 41: 807-10.
15. Sheikine Y, Genega E, Melamed J, Lee P, Reuter VE, Ye H. Molecular genetics of testicular germ cell tumors. Am J Cancer Res 2012; 2: 153-67.
16. Koul S, Houldsworth J, Mansukhani MM, et al. Characteristic promoter  hypermethylation signatures in male germ cell tumors. Mol Cancer 2002; 1: 8.
17. Mortensen MS, Gundgaard MG, Lauritsen J. A nationwide cohort study of surveillance for stage I seminoma. J Clin Oncol 2013; 31: Suppl. abstract no. 4502.
18. Soper MS, Hastings JR, Tome M, Lodin K. Observation versus adjuvant radiation or chemotherapy in the management of stage I seminoma. J Clin Oncol 2011; 29: Suppl. abstract no. 4596.
19. Oldenburg J, Foss. SD, Nuver J, et al. Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24: Suppl 6: vi125-vi132. abstract.
20. Oliver RT, Mead GM, Rustin GJ, et al. Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). J Clin Oncol 2011; 29: 957-62.
21. Tandstad T, Cavilin-Shahl E, Dahl O, et al. Management of clinical stage I seminomatous testicular cancer: a report from SWENOTECA. J Clin Oncol 2014; 32:5s.abstract no. 4508.
22. Domont J, Massard C, Patrikidou A, et al. A risk-adapted strategy of radiotherapy or cisplatin-based chemotherapy in stage II seminoma. Urol Oncol 2013; 31: 697-705.
23. De Santis M, Becherer A, Bokemeyer C, et al. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol 2004; 22: 1034-9.
24. Kollmannsberger C, Tandstad T, Bedard PL, et al. Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance. J Clin Oncol 2014 August 18 (Epub ahead of print).
25. Schmoll HJ, Jordan K, Huddart R, et al. Testicular non-seminoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20: Suppl 4: 89-96.
26. Tandstad T, Dahl O, Cohn-Cedermark G, et al. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. J Clin Oncol 2009; 27: 2122-8.
27. Nichols CR, Roth B, Albers P, et al. Active surveillance is the preferred approach to clinical stage I testicular cancer. J Clin Oncol 2013; 31: 3490-3.
28. Albers P, Siener R, Krege S, et al. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol 2008; 26: 2966-72.
29. de Wit R, Bosl GJ. Optimal management of clinical stage I testis cancer: one size does not fit all. J Clin Oncol 2013; 31: 3477-9.
30. Westermann DH, Studer UE. High risk clinical stage I nonseminomatous germ cell tumors: the case for chemotherapy. World J Urol 2009; 27: 455-61.
31. Donohue JP, Thornhill JA, Foster RS, Bihrle R, Rowland RG, Einhorn LH. The role of retroperitoneal lymphadenectomy in clinical stage B testis cancer: the Indiana University experience (1965 to 1989). J Urol 1995; 153: 85-9.
32. Ehrlich Y, Brames MJ, Beck SD, Foster RS, Einhorn LH. Long-term follow-up of cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission? J Clin Oncol 2010; 28: 531-6.
33. Oldenburg J, Alfsen GC, Lien HH, Aass N, Waehre H, Fossa SD. Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses. J Clin Oncol 2003; 21: 3310-7.
34. O’Donnell E, Gray KP, Ravi P, et al. A meta-analysis of patient outcomes with sub centimeter disease after chemotherapy for metastatic nonseminomatous germ cell tumor (NSGCT). J Clin Oncol 2013; 31: Suppl 6: 324. abstract.
35. Bosl GJ, Geller NL, Bajorin D, et al. A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors. J Clin Oncol 1988; 6: 1231-8.
36. Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987; 316: 1435-40.
37. Einhorn LH, Williams SD, Loehrer PJ, et al. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. J Clin Oncol 1989; 7: 387-91.
38. de Wit R, Roberts JT, Wilkinson PM, et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 2001; 19: 1629-40.
39. Culine S, Kerbrat P, Kramar A, et al. Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). Ann Oncol 2007; 18: 917-24.
40. de Wit R, Skoneczna I, Daugaard G, et al. Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: intergroup study EORTC 30983. J Clin Oncol 2012; 30: 792-9.
41. Nichols CR, Catalano PJ, Crawford ED, Vogelzang NJ, Einhorn LH, Loehrer PJ. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol 1998; 16: 1287-93.
42. Motzer RJ, Nichols CJ, Margolin KA, et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol 2007; 25: 247-56.
43. Droz JP, Kramar A, Biron P, et al. Failure of high-dose cyclophosphamide and etoposide combined with double-dose cisplatin and bone marrow support in patients with high-volume metastatic nonseminomatous germ-cell tumours: mature results of a randomised trial. Eur Urol 2007; 51: 739-46.
44. Daugaard G, Skoneczna I, Aass N, et al. A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer: an intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). Ann Oncol 2011; 22: 1054-61.
45. Fizazi K, Pagliaro LC, Flechon A, et al. A phase III trial of personalized chemotherapy based on serum tumor marker decline in poor-prognosis germ-cell tumors: results of GETUG 13. J Clin Oncol 2013; 31: Suppl. abstract no. LBA4500.
46. Loehrer PJ Sr, Lauer R, Roth BJ, Williams SD, Kalasinski LA, Einhorn LH. Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med 1988; 109: 540-6.
47. Loehrer PJ Sr, Gonin R, Nichols CR, Weathers T, Einhorn LH. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 1998; 16: 2500-4.
48. Kondagunta GV, Bacik J, Donadio A, et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol 2005; 23: 6549-55.
49. Einhorn LH, Williams SD, Chamness A, Brames MJ, Perkins SM, Abonour R. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med 2007; 357: 340-8.
50. Feldman DR, Sheinfeld J, Bajorin DF, et al. TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. J Clin Oncol 2010; 28: 1706-13.
51. Rosenberg B, Vancamp L, Krigas T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 1965; 205: 698-9.
52. Einhorn LH, Donohue J. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 1977; 87: 293-8.
53. International Germ Cell Cancer Collaborative Group. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997; 15: 594-603.
54. Feldman DR, Hu J, Dorff TB, et al. Paclitaxel, ifosfamide, and cisplatin (TIP) efficacy for first-line treatment of patients (pts) with intermediate- or poor risk germ cell tumors (GCT). J Clin Oncol 2013; 31: Suppl. abstract no. 4501.
55. Nichols CR, Tricot G, Williams SD, et al. Dose-intensive chemotherapy in refractory germ cell cancer — a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 1989; 7: 932-9.
56. Pant-Purohit M, Brames M, Abonour R, et al. Tumor marker rise during second course high dose chemotherapy in recurrent testicular cancer: outcome analysis. J Bone Marrow Res 2013; 1: 118
57. Feldman D, Voss M, Jia X, et al. Serum tumor marker (STM) decline rates during high-dose chemotherapy (HDCT) to predict outcome for germ cell tumor (GCT) patients (pts). J Clin Oncol 2012; 30: Suppl. abstract no. 4532.
58. Pico JL, Rosti G, Kramar A, et al. A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol 2005; 16: 1152-9.
59. Lorch A. Superior survival after sequential high-dose chemotherapy (HDCT) as compared to single HDCT in patients with relapsed or refractory germ cell tumors (GCT): six-year long term follow-up of a prospective, randomized phase II trial. J Clin Oncol 2011; 29: Suppl. Abstract no. 4507.
60. Lorch A, Bascoul-Mollevi C, Kramar A, et al. Conventional-dose versus high dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol 2011; 29: 2178-84.
61. van Walraven C, Fergusson D, Earle C, et al. Association of diagnostic radiation exposure and second abdominal-pelvic malignancies after testicular cancer. J Clin Oncol 2011; 29: 2883-8.
62. Travis LB, Beard C, Allan JM, et al. Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst 2010; 102: 1114-30.
63. Fung C, Fossa SD, Milano MT, Oldenburg J, Travis LB. Solid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study. J Clin Oncol 2013; 31: 3807-14.
64. Horwich A, Fossa SD, Stenning SP, et al. Risk of second cancers among a cohort of 2,703 long-term survivors of testicular seminoma treated with radiotherapy. J Clin Oncol 2010; 28: 15s. abstract no. 4538.
65. Abouassaly R, Fossa SD, Giwerecman A, et al. Sequelae of treatment in longterm survivors of testis cancer. Eur Urol 2011; 60: 516-626.
66. Willemse PM, Burggraaf J, Hamdy NA, et al. Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors. Br J Cancer 2013; 109: 60-7.
67. Haugnes HS, Wethal T, Aass N, et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol
2010; 28: 4649-57.
68. Shinn EH, Swartz RJ, Thornton BB, Spiess PE, Pisters LL, Basen-Engquist KM. Testis cancer survivors’ health behaviors: comparison with age-matched relative and demographically matched population controls. J Clin Oncol 2010; 28: 2274-9.
69. Sprauten M, Bryd.y M, Haugnes HS, et al. Longitudinal serum testosterone, luteinizing hormone, and follicle-stimulating hormone levels in a population based sample of long-term testicular cancer survivors. J Clin Oncol 2014; 32: 571-8.
70. Einhorn LH, Brames MJ, Heinrich MC, Corless CL, Madani A. Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT. Am J Clin Oncol 2006; 29: 12-3.
71. Feldman DR, Turkula S, Ginsberg MS, et al. Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors. Invest New Drugs 2010; 28: 523-8.
72. Rick O, Braun T, Siegert W, Beyer J. Activity of thalidomide in patients with platinum-refractory germ-cell tumours. Eur J Cancer 2006; 42: 1775-9.
73. Kollmannsberger C, Pressler H, Mayer F, Kanz L, Bokemeyer C. Cisplatin-refractory, HER2/neu-expressing germ-cell cancer: induction of remission by the monoclonal antibody trastuzumab. Ann Oncol 1999; 10: 1393-4.




Usted debe ingresar al sitio con su cuenta de usuario IntraMed para ver los comentarios de sus colegas o para expresar su opinión. Si ya tiene una cuenta IntraMed o desea registrase, ingrese aquí

Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2020